On July 20, 2026, Sunshine Biopharma Inc. entered into an At-The-Market Issuance Sales Agreement with Aegis Capital Corp. to sell up to $4,000,000 of common stock. Aegis Capital Corp. will act as the exclusive sales agent and receive a commission of 3.0% of the gross proceeds. The shares will be issued under a shelf registration statement on Form S-3. Sunshine Biopharma Inc. is a biopharmaceutical company.

Sunshine Biopharma Inc. entered into a Release Agreement with Malek Chamoun, the former president of Nora Pharma Inc., a wholly-owned subsidiary, on July 8, 2026, to settle a dispute. The company agreed to pay CAD$1,500,000 (approximately US$1,058,565) in full and final settlement. Sunshine Biopharma Inc. operates in the biopharma industry and develops products for ocular-related diseases.